Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies

Robert C Smallridge¹, Laura A Marlow² and John A Copland²

¹Division of Endocrinology, Department of Internal Medicine and ²Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32224, USA

(Correspondence should be addressed to R C Smallridge; Email: smallridge.robert@mayo.edu)

Abstract

Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam radiation therapy has improved locoregional control, the median survival of ~ 4 months has not changed in more than half a century due to uncontrolled systemic metastases. The objective of this study was to review the literature in order to identify potential new strategies for treating this highly lethal cancer. PubMed searches were the principal source of articles reviewed. The molecular pathogenesis of ATC includes mutations in BRAF, RAS, catenin (cadherin-associated protein), beta 1, PIK3CA, TP53, AXIN1, PTEN, and APC genes, and chromosomal abnormalities are common. Several microarray studies have identified genes and pathways preferentially affected, and dysregulated microRNA profiles differ from differentiated thyroid cancers. Numerous proteins involving transcription factors, signaling pathways, mitosis, proliferation, cell cycle, apoptosis, adhesion, migration, epigenetics, and protein degradation are affected. A variety of agents have been successful in controlling ATC cell growth both in vitro and in nude mice xenografts. While many of these new compounds are in cancer clinical trials, there are few studies being conducted in ATC. With the recent increased knowledge of the many critical genes and proteins affected in ATC, and the extensive array of targeted therapies being developed for cancer patients, there are new opportunities to design clinical trials based upon tumor molecular profiling and preclinical studies of potentially synergistic combinatorial novel therapies.

Incidence

Thyroid cancers, while uncommon, are increasing in prevalence in this country due, at least in part, to earlier detection from imaging. In 2008, there are estimated to be 37 340 new cases, with 1590 deaths (Jemal et al. 2008). Anaplastic thyroid carcinomas (ATCs) are estimated to comprise 1–2% of thyroid malignancies. Unfortunately, their rapid onset and fulminant course have not altered their detection or outcomes. This review will analyze their molecular pathogenesis, the results of preclinical studies and clinical management, and discuss possible new treatment strategies.

Molecular pathogenesis

Mutations

More than 90% of all thyroid cancers derive from the thyroid follicular cell, including papillary (PTC), follicular (FC), or Hurthle cell. ATC may derive de novo or from pre-existing PTC or FC. A small number of gene mutations have been identified, and there appears to be a progression in mutations acquired during dedifferentiation. Several mutations occurring in PTC (e.g., RAS and BRAF) are also seen in ATC, suggesting these are early events (Nikiforov 2004). Late mutations include TP53, catenin (cadherin-associated protein), beta 1, and PIK3CA, suggesting that one or more of these mutations contribute to the extremely aggressive behavior of ATC. By contrast, the RET/PTC rearrangements found in childhood and radiation-induced PTCs, and the PAX8/PPARG fusion protein detected in follicular carcinoma, are not observed in poorly differentiated and ATCs (Nikiforov 2004; Table 1).

RAS

The RAS family of oncogenes regulate two important signaling pathways in thyroid cancer, the

BRAF
BRAF is a serine/threonine kinase involved in cell proliferation. The most common mutation in papillary thyroid cancer is BRAF. It, too, is highly variable in ATC, ranging from 0 to 50%, due, in part, to small sample sizes and different laboratory methodologies. When ATCs with a papillary component were examined, this mutation was observed in both the differentiated and undifferentiated regions (Begum et al. 2004, Soares et al. 2004, Takano et al. 2007a).

TP53
The TP53 tumor suppressor gene (chromosome 17p) increases the cyclin kinase inhibitor, p21, promoting cell cycle arrest at G1/S, but is commonly mutated in cancer. Mutations impair TP53 transcriptional activity, and occur in 55% of ATCs (Donghi et al. 1993, Fagin et al. 1993, Zou et al. 1993, Zdenius et al. 1996, Nikiforov 2004). Elevated levels can also be detected by immunohistochemistry (IHC; Lam et al. 2000, Quiros et al. 2005), which may reflect altered function without mutation (Malaguarnera et al. 2007, Wreesmann & Singh 2008). Boltze et al. (2002) examined a common polymorphism (codon 72, exon 4) of the TP53 gene. Homozygous proline was present in 100% of 22 ATC patient tumors, but in no benign nodules or differentiated thyroid cancers, suggesting this polymorphism may be a risk factor.

Wnt pathway genes
The catenin (cadherin-associated protein), beta 1 gene is involved in Wnt signaling and cell–cell adhesion. Both mutations and abnormal nuclear localization are seen in malignancies. Mutations were detected in 61% of 31 ATC cases (with nuclear localization in half with mutations) (Garcia-Rostan et al. 1999), while abnormalities were detected in 32% of poorly differentiated (Garcia-Rostan et al. 2001), but no papillary or follicular thyroid cancers (Garcia-Rostan et al. 2001, Miyake et al. 2001). By contrast, Rocha et al. (2003) evaluated 17 poorly differentiated (but no anaplastic) thyroid cancers. They found loss of cadherin 1, type 1, E-cadherin (epithelial) membrane expression, but no nuclear localization of catenin (cadherin-associated protein).

Table 1 Mutations in anaplastic thyroid carcinomas

<table>
<thead>
<tr>
<th>References</th>
<th>Ras</th>
<th>BRAF</th>
<th>TP53</th>
<th>Catenin&lt;sup&gt;a&lt;/sup&gt;, beta 1</th>
<th>PIK3CA</th>
<th>Axin</th>
<th>APC</th>
<th>PTEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fagin et al. (1993)</td>
<td>5/6</td>
<td></td>
<td></td>
<td>19/31</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donghi et al. (1993)</td>
<td>5/7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zou et al. (1993)</td>
<td>1/5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zdenius et al. (1996)</td>
<td>1/4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garcia-Rostan et al. (1999)</td>
<td>15/29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garcia-Rostan et al. (2003)</td>
<td>2/7</td>
<td>0/7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fukushima et al. (2003)</td>
<td>2/7</td>
<td>0/7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Namba et al. (2003)</td>
<td>2/6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nikiforova et al. (2003)</td>
<td>3/29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soares et al. (2004)</td>
<td>6/17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Begum et al. (2004)</td>
<td>8/16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kunihara et al. (2004)</td>
<td></td>
<td></td>
<td>1/22</td>
<td>16/70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quiros et al. (2005)</td>
<td>1/8</td>
<td>5/8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garcia-Rostan et al. (2005)</td>
<td>4/20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Takano et al. (2007a)</td>
<td>1/7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitsiades et al. (2007)</td>
<td>4/50</td>
<td>14/49</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hou et al. (2007) and</td>
<td>6/50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liu et al. (2008)</td>
<td>8/48</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Santarpia et al. (2008)</td>
<td>2/36</td>
<td>9/36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Costa et al. (2008)</td>
<td>13/36</td>
<td>9/36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (%)</td>
<td>37/166</td>
<td>61/231</td>
<td>12/22</td>
<td>20/53</td>
<td>27/156</td>
<td>18/22</td>
<td>2/22</td>
<td>10/84</td>
</tr>
</tbody>
</table>

<sup>a</sup>(cadherin associated protein)
PIK3CA
PI3K is a kinase that phosphorylates AKT1 isoforms. They, in turn, phosphorylate substrates involved in cell growth and survival. PIK3CA encodes a catalytic subunit of PI3K (Santarpia et al. 2008). PIK3CA (located on 3q26.3) was mutated in 12–23% of ATC cases (Garcia-Rostan et al. 2005, Hou et al. 2007, Liu et al. 2008, Santarpia et al. 2008) and copy gains occurred in 38–61% (Hou et al. 2007, Liu et al. 2008, Santarpia et al. 2008). Mutations were infrequently present in follicular (6–13%) or papillary (1–3%) tumors (Garcia-Rostan et al. 2005, Hou et al. 2007, Wang et al. 2007, Liu et al. 2008). AKT1 was activated in most ATC cases (85–93%) (Garcia-Rostan et al. 2005, Santarpia et al. 2008) and ERK was activated in 65% (Santarpia et al. 2008). Phosphatase and tensin homology encoding chromosome 10 (PTEN) negatively regulates the PI3K pathway was mutated in 17% of 48 cases (Liu et al. 2008).

RET
RET, a proto-oncogene that encodes a receptor tyrosine kinase, is mutated in familial medullary thyroid carcinoma, and RET/PTC rearrangements occur in PTC. RET was amplified in seven ATCs (Nakashima et al. 2007), and three had increased TP53 by IHC, suggesting genomic instability from aberrant TP53 may have led to the RET abnormality.

Cytogenetic analyses
Cytogenetic metaphase analysis of ATC was reported more than 20 years ago (Mark et al. 1987), while comparative genomic hybridization (CGH) has permitted detection of deletions or amplifications in chromosomal regions not identified by conventional cytogenetics or FISH analysis (Inazawa et al. 2004). Modification using array-CGH (a-CGH) has further improved genome-wide detection of regions that may harbor cancer associated genes (Inazawa et al. 2004). While the methodology does not identify specific genes, it locates regions of chromosomal instability for more focused investigations (Pinkel & Albertson 2005).

The role of a-CGH in clinical practice, whether whole-genome screening or targeted arrays, is currently being discussed (Bejjani & Shaffer 2006, Done 2006, Veltman & de Vries 2006). While copy number variations are common and can potentially confound data interpretation (Gunn et al. 2007), the potential to integrate a-CGH results with histopathology and other molecular markers, and to relate the laboratory findings with patient diagnosis, prognosis, and therapy, will bring an individualized approach to cancer therapy in clinical practice (Climent et al. 2007).

Chromosomal aberrations in ATC
Mark et al. (1987) performed metaphase analyses on five ATC patients; three had 10q aberrations, and two had 3p25 abnormalities (Table 2). RET resides on 10q11.2 and PTEN on 10q23.3, while hypoploidy of 3p is common in follicular and Hürthle cell cancers. In two patients with complex clonal karyotypes, abnormalities were detected in 16 separate chromosomes, with both tumors having clones with losses of chromosome 8 and both sex chromosomes (Jenkins et al. 1990).

In the first report of CGH in ATC patients, DNA copy number changes were found in 11 out of the 13, gains were noted in 10 out of the 13, deletions in 3 out of the 13, both gains and deletions in two, and chromosomal deletion in one. Overall, there were 27 gains and five deletions. Common gains included chromosomes 7p22-pter, 8q22-qter, and 9q34-qter, regions that harbor the PDGRα, myc, and ABL1 genes respectively (Hemmer et al. 1999).

CGH studies in nine cases of ATC showed five had giant cell and four had spindle cell histology, with none having antecedent differentiated thyroid cancer (Wilkens et al. 2000). The most common gains or losses occurred in chromosomes 8p and 8q, and amplification of 5p. Fourteen additional chromosomes had imbalances in one or two of the tumors, and two cell lines had similar findings. The authors were uncertain of the role of chromosome 5 and 8 aberrations in ATC, but noted that p45 skp2 and c-myc genes resided on 5p and 8q24 (Wilkens et al. 2000). Kitamura et al. (2000) detected allelic losses in 16 out of the 21 ATCs studied, including loss of 22q in 38%. CBX7, a putative tumor suppressor, resides on 22q13.1 and is markedly under expressed in ATC (Pallante et al. 2008). Loss of 22q has been shown by others (Table 2).

CGH was performed on 15 well differentiated, 12 poorly differentiated, and 15 ATC samples to look for changes associated with tumor progression.
(Wreesmann et al. 2002). Both frequency and number of CGH abnormalities were identified in more undifferentiated tumors. All three tumor types had chromosomal gains at 5p15 (telomerase reverse transcriptase location), 5q11–13, 19p, 19q (the zinc finger TF ZN331 on 19q13.3, a frequent break point, is common in follicular adenomas and often involved in a translocation with 5q13), and losses at 8p. The poorly differentiated and anaplastic cancers had additional gains at 1p34–36 (stathmin location), 6p21 (location of p38α- and δ MAP kinases), 9q34, 17q25 (survivin location), 20q, and losses at 1p11–31, 2q32–33, 4q11–13, 6q21, and 13q21–31. Unique to ATC were gains at 3p13–14 and 11q13 (CCND1 (cyclin D1) and FOSL1 location), and losses at 5q11–31. The authors cited a number of potentially affected genes identified in regions of chromosomes 1p, 3p, 5q, 11q, 13q, 17q, 20q including HTIF1, Wnt5A, APC, Wnt 11, LGALS3BP (galectin-3 binding protein; mediates cell–cell and cell–matrix interactions), SIRT8 (a proto-oncogene of unknown function), MMP9, MMP24, LAMBA5, and syndecan-4 (complexes with CXCR4).

Miura et al. (2003) performed CGH on ten ATC samples, six associated with papillary and two with follicular thyroid cancer. Five patients had 24 cytogenetic abnormalities, 22 were gains and two were losses. The most frequent aberration was a gain in 1q (common in many cancers) in three out of the ten cases. The two losses were in 9q22.3–32 and 3p12.2–21.3, a region also detected by others (Wreesmann et al. 2002). The authors were unable to show any correlation of the CGH aberration with survival or other clinical parameters (Miura et al. 2003).

Rodrigues et al. (2004) examined seven ATCs; all had chromosomal imbalances. Three were gains at 20p and 20q, and losses of Xp in six cases, gains at 3q and 5p in five cases. 7q31 was often deleted. Important genes included PI3K, BCL6 (codes Zn finger protein that represses transcription) and SST at 3q, the invasion and metastases genes (MMP9 and MMP24), cell cycle and checkpoint gene (STK15) at 20q, and Fra7G at 7q.

Three recent reports examined ATC cell lines by array-CGH. Rodrigues et al. (2007) found high level amplification at 3q24, 5p, 7p (EGFR location), 7q (MET and BRAF location), 12p (K–RAS location), 14q, and 20. Lee et al. (2007) tested two novel and six established ATC cell lines. Gains and losses were

### Table 2 Cytogenetic analyses in patients with anaplastic thyroid cancer

<table>
<thead>
<tr>
<th>References</th>
<th>Patients (n)</th>
<th>Cell lines (n)</th>
<th>Gains</th>
<th>Losses</th>
<th>Both</th>
<th>Chromosomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jenkins et al. (1990)</td>
<td>2</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Complex clonal karyotype; loss of eight (both); x; y –2, –4, –8, –9, +11, –13, +14, –14, +15, –17, –19, –20, –21, –22, –x, –y +7p (31%); +8q (23%); +9q (23%)</td>
</tr>
<tr>
<td>Hemmer et al. (1999)</td>
<td>13</td>
<td>–</td>
<td>10/13</td>
<td>3/13</td>
<td>2/13</td>
<td>Gains in 14 chromosomes; losses in eight chromosomes; most common: 5p amplified; 8p, 8q gains or losses</td>
</tr>
<tr>
<td>Wilkens et al. (2000)</td>
<td>9</td>
<td>2</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Allelic losses 16/21; Losses: 1q (40%); 9p (58%); 11p (33%); 11q (33%); 17p (44%); 17q (43%); 19p (36%); 22q (38%)</td>
</tr>
<tr>
<td>Kitamura et al. (2000)</td>
<td>21</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Early Gains: 5, 8, 19; losses: 8, 22; intermediate: gains: 1, 6, 9, 17, 20; losses: 1, 2, 6, 13 late: gains: 3p, 11q; losses: 5q</td>
</tr>
<tr>
<td>Wreesmann et al. (2002)</td>
<td>15</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Gains in all chromosomes; losses less common; high amplification in: 5p, 5p, 6p, 9p, 12p, 14q, 18p</td>
</tr>
<tr>
<td>Miura et al. (2003)</td>
<td>10</td>
<td>1</td>
<td>5/10</td>
<td>2/10</td>
<td>–</td>
<td>Gains: 1, 4, 5, 6, 7, 10, 14, 16, 19, 20, 21, x; losses: 3p; 9q</td>
</tr>
<tr>
<td>Rodrigues et al. (2004)</td>
<td>7</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Amplifications: 3q24; 5p; 7p; 7q; 12p; 14q; 20</td>
</tr>
<tr>
<td>Rodrigues et al. (2007)</td>
<td>–</td>
<td>3</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Frequent: gains: 8q; 11q; 19; 20q; losses: 4q; amplification: 8q</td>
</tr>
<tr>
<td>Lee et al. (2007)</td>
<td>–</td>
<td>8</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Gains: 1q21; 6p22-p21; 7q11.22-11.23; 11q13; 12q13; 16p11.2; 17q21; 19p13; 19q13; 1-q13.2; 20q11.2; 20q13.12; 22q11.21; 22q13.1 Losses: 4q12-q13.1; 4q28.3; 13q21.2-q21.31</td>
</tr>
<tr>
<td>Lee et al. (2008)</td>
<td>27</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
</tbody>
</table>

(R C Smallridge et al.: Anaplastic thyroid cancer)
prevalent throughout with high level amplification at 1p, 8q (myc location), 9q, 11q, and 20q. FISH analysis showed gains in seven out of the eight cell lines for UBE2C (20q13.12), a gene overexpressed in ATC (Pallante et al. 2005). Lee et al. (2008) performed array-CGH to analyze for genome-wide copy number changes in 27 ATC tissues. An average of 44 copy number changes was detected in each tumor. Frequent gains were noted at 11q13 (site of CCND1 (cyclin D1)), which was expressed in 18 out of the 27 tissues and also FOSL1, 16p11.2, 20q11.2, and 20q13.12 (UBE2C location). Loss of the CDKN2A locus on 9p21.3 was confirmed by finding undetectable p16 protein in 24 out of the 27 ATC tissues (Lee et al. 2008). 

Liu et al. (2008) analyzed up to 51 ATCs for copy number gains in receptor tyrosine kinase genes and in PI3K and BRAF pathway genes. Copy number gains were detected in EGFR and VEGFR1 (46%); PDGFRB, PIK3Cα and PIK3Cb (38%); PDGFRα (24%); KIT (22%); PDK1 (20%); AKT1 (19%); VEGFR2 (17%); and MET (12%). Overall, at least one copy number gain was present in 80.4% of cases (Liu et al. 2008).

These studies emphasize that ATCs have a high degree of numeric and structural genomic disarray. These abnormalities likely result in substantial gene expression changes in many genes. This high degree of disarray and the rarity of these tumors make it difficult to determine which targets of instability are selected for or convey growth advantages.

**MicroRNA**

A new level of the regulation of cell growth and survival has emerged with the recent discovery of microRNAs (Table 3). These molecules are small (~22 nucleotides), single stranded, non-coding RNAs. There are estimated 300–1000 microRNAs, each of which may bind to several hundred gene targets. Most often, they appear to repress gene expression post-transcriptionally (so that protein, not RNA, levels are reduced) (Esquela-Kerscher & Slack 2006), but they can also affect mRNA degradation (Volinia et al. 2006). MicroRNAs can act as oncogenes or tumor suppressor genes and, given their pleiotropic effects, can perform both functions in the same cell (Calin et al. 2004, Calin & Croce 2006, Esquela-Kerscher & Slack 2006).

MicroRNA (miR) expression can be altered in several ways, such as abnormalities in their large RNA precursors, their tendency to reside in cancer-associated genomic regions, or by epigenetic silencing (Calin et al. 2004, Calin & Croce 2006, Meng et al. 2006, Saito & Jones 2006, Zhang & Coukos 2006). MicroRNAs play an important role in oncogenesis, and expression profiles or fingerprints may improve the specificity of diagnosis, therapy, and prognosis (Lu et al. 2005, Calin & Croce 2006, Volinia et al. 2006, Blower et al. 2008).

MicroRNAs may become therapeutic targets themselves (Jeyaseelan et al. 2007), and both overexpression and inhibition of their activity have influenced cellular growth and tumor responses to other chemotherapy agents (Meng et al. 2006, Blower et al. 2008). Downstream targets of these miRs are known in some instances, and the manipulation of miR expression can directly affect target genes. For example, miR-21 is overexpressed in cholangiocarcinoma, the miR-21 precursor reduces PTEN expression, and inhibition of miR-21 reduces the p85 subunit of PI3K (Meng et al. 2006). Similarly, miR-21 is overexpressed in glioblastomas, and its inhibition increases caspases and apoptosis (Chan et al. 2005).

While most studies in cancer have shown that miRs are underexpressed, overexpression may also contribute to oncogenesis or tumor progression, as in thyroid malignancies. Most thyroid cancers derive from the follicular cell. He et al. (2005) demonstrated that miRs are up-regulated in papillary thyroid carcinoma (PTC). The most highly expressed were miRs -221, -222, and -146. Other miRs overexpressed greater than twofold were -21, -220, -181, and -155. Underexpressed miRs included -138, -219, -26a, and -345. Pallante et al. (2005) identified five overexpressed miRs and suggested that -221, -222, and -181b could be a signature for PTC. The observation on miR-221 and -222 was extended by showing that forced overexpression would reduce p27kip1 protein and increase G1- to S-phase transition (Visone et al. 2007a). These observations suggest that miR-221 and -222 could be therapeutic targets in PTC. Four microRNAs (-197, -346, -192, and -328) were found overexpressed in FTC (Weber et al. 2006).

Four miRs (-30d, -125b, -26a, and 30a-5p) were underexpressed in ATC, but not in PTC (Visone et al. 2007b). Both miR-26a and -125b may target HMGA1 and HMGA2, two proteins involved in thyroid cell transformation (Berlingieri et al. 2002). These authors also showed that miR-138 was reduced, and miR-222 (increased in PTC) also was overexpressed (1.98 fold) in ATC.

Mitomo et al. (2008) showed that miRs-21, -146b, -221, and -222 were up-regulated in both ATC and PTC. MiR-21 targets E2F (involved in cell cycle and apoptosis) and inhibits PTEN. Down-regulated miRs included -26a, -138, -219, and -345. They also found that hTERT, a possible gene target for miR-138, was
reduced and experimentally, hTERT protein could be reduced by overexpressing miR-138. The miR-17–92 cluster of seven miRNAs as well as miR-106a and -106b were overexpressed in cell lines, and in three out of the six ATC patient samples, miR-17-3p and -17-5p were overexpressed (Takakura et al. 2008). Antisense inhibitors to miRs 17-3p, -17-5p, and -19a all inhibited cell growth, suggesting an oncogenic role for these miRs. Other miRs in the cluster (i.e., miR-19a and -19b) have PTEN as a target, and miR-106a and -106b have E2F1 as a target. Thus, there are multiple potential therapeutic targets in the miR-17–92 cluster (Takakura et al. 2008).

Although microRNA research is still young, it is gratifying that studies of miRs expression and function already exist for three principal types of thyroid cancer. The results suggest that each has several miRs distinct for that particular type of thyroid cancer. Thus, studies of miRs in thyroid oncogenesis hold promise to improve the evaluation and management of these tumors.

### Functional genomics

#### Gene microarray

Gene expression microarrays have provided valuable insights into the molecular pathogenesis of thyroid cancer. Numerous studies have identified multiple over- and underexpressed genes involved in the regulation of critical cell functions (e.g., oncogenes, tumor suppressor genes, signaling pathways, transcription factors, cell adhesion, thyroid functions, invasion, chemokines, etc. (Riesco-Eizaguirre & Santisteban 2007)). Various authors have employed this technology to identify differences amongst thyroid tumor types (Finley et al. 2004, Frattini et al. 2004, Mazzanti et al. 2004, Wreesmann et al. 2004, Giordano et al. 2005, Melillo et al. 2005, Eszlinger et al. 2007). In a meta-review of 21 studies, of 1785 genes differentially expressed, there were 39 felt to be most reliable amongst overlap comparisons. Only one of the studies involved anaplastic patients (Griffith et al. 2006).

Only a few studies have examined gene expression by microarray in ATC cell lines or patient samples. Onda et al. (2004b) utilized 11 ATC cell lines and ten patient samples. They found 31 genes over- and 56 genes underexpressed in cell lines. Functions affected pertinent to cancer cells include: Rab proteins localization (GD12), cell structure and endocytosis (destrin), microtubules (stathmin), and RaF inhibition (PBP; Onda et al. 2004b). Salvatore et al. (2007) did a microarray screen on five ATC samples, and validation on 22. They found 114 genes that distinguished ATC and PTC samples from normal thyroid, and 54 cell cycle progression and chromosome instability related genes up-regulated in ATC. Montero-Conde et al. (2008) examined seven ATC, six poorly differentiated, and 31 well-differentiated thyroid cancer patients by microarray. Pathways preferentially dysregulated in PDTC and ATC tissues were MAPK, cell cycle, focal adhesion, cytoskeleton, and TGFB1.
Pallante et al. (2008) detected a marked down-regulation of CBX7 expression by microarray and showed that mRNA for CDKN2A/p16, a tumor suppressor and target of CBX7, was highly overexpressed.

**Proteins expression**

While identifying altered expression of genes gives important clues, assessment of proteins expression yields more direct evidence of cellular functions that are dysregulated in cancer cells. Effects manifest themselves at the level of oncogene and tumor suppressor gene functions, receptors and signaling pathways, nuclear and organelle events, cell cycle, cell division, cellular death, adhesion, and migration. All of these functions have been studied to some degree in ATC, and these observations proffer diagnostic and therapeutic opportunities (Table 4).

**Transcription factors**

Thyroid transcription factors (NKX2-1 and FOXE1) and paired box gene 8 (Pax 8) regulate expression of thyroid specific proteins including thyroglobulin, TSHR, thyroid peroxidase, and NA$_{1}$/I$^{-}$ symporter. Their protein expression becomes reduced or absent as follicular cell dedifferentiation progresses. The mRNAs for NKX2-1 (Ros et al. 1999, Takano et al. 2007b), FOXE1 (Sequeira et al. 2001), and Pax 8 (Ros et al. 1999) are also reduced or absent in ATCs.

Peroxisome proliferator-activated receptor gamma (PPARG) is a transcription factor affecting adipogenesis and differentiation. PPARG agonists have anti-tumor activity in a variety of malignancies (Copland et al. 2006b), and inhibition of PPARG function contributes to follicular thyroid cancer indicating tumor suppressive activity of PPARG (Kroll et al. 2000, Kato et al. 2006). ATC cell lines express functionally active nuclear PPARG protein (Hayashi et al. 2004, Aiello et al. 2006, Copland et al. 2006b) and the protein is present in at least 84% of patient ATC samples (unpublished observations).

Hepatocyte nuclear factor-1α (HNF-1α) plays a role in glucose metabolism, and may also influence carcinogenesis. Both HNF-1α mRNA and protein were present in ATC cell lines. Transcripts were also present in most ATC but not PTC tissue samples, suggesting a role for HNF-1α in more aggressive thyroid cancer (Xu et al. 2008).

The growth promoting transcriptional factor E2F1 is regulated by the tumor suppressor retinoblastoma gene, and its mRNA was up-regulated in 11 ATC cell lines, as well as most PTC lines (Onda et al. 2004a). By contrast, transcription elongation factor A (S11) like 4 (TCEAL4) mRNA was down-regulated in both ATC cell lines and tissues (Akaishi et al. 2006). Id (inhibitor of DNA binding) proteins have a dominant negative effect on gene transcription and enhance cell proliferation. Up-regulation appears early and is detected in follicular adenomas, but the highest percentage was detected in ATC tissues (Kebebew et al. 2004).

The Y-box binding protein 1(YBX1) interacts with inverted CCAAT nucleotide sequences, and was overexpressed in 27 out of the 28 ATC patients (Ito et al. 2003b). The CCAAT nucleotide sequence is present in several important cancer promoting genes including the EGFR, multi-drug resistance 1, proliferating cell nuclear antigen, and DNA topoisomerase 11α (Ito et al. 2003b). The high mobility group I (Y) gene transcribes nuclear proteins, and is overexpressed in ATC cell lines (Scala et al. 2000). HMG1 proteins may suppress expression of CBX7, a protein that represses gene transcription and growth rate (Pallante et al. 2008). The FOSL1 protein, a transcription factor in the AP-1 complex that is involved in cell transformation, is expressed in thyroid adenomas and in differentiated as well as ATCs (Chiapetta et al. 2000), while c-myc is overexpressed in 59% of 22 ATC tissues (Kurihara et al. 2004).

**Signaling pathways**

The EGFR is a cell surface receptor which activates several intracellular tyrosine kinase regulated pathways (e.g., MAPK; PI3K) involved in proliferation, migration, etc., in many cancers. It is not detectable in normal thyroid tissues, and rarely in papillary thyroid carcinoma (Schiff et al. 2004, Elliott et al. 2008). However, it is detected in 58–87% of anaplastic tissues (Ensinger et al. 2004, Schiff et al. 2004, Wiseman et al. 2007b, Elliott et al. 2008) and in cell lines (Schiff et al. 2004).

Chemokine receptors also activate multiple downstream signaling pathways, including PI3K. CXCR4 is overexpressed in many cancers, and recently has been shown to be overexpressed in both ATC cell lines and patient samples (De Falco et al. 2007). A source of chemokines may be their paracrine secretion by tumor-associated microphages, present in 19 out of the 20 ATC samples (Ryder et al. 2008).

The RAS–RAF–MEK–ERK and PI3K pathways are both involved in the pathogenesis of papillary and follicular thyroid cancers (Shinohara et al. 2007), and mutation in one of the genes regulating either pathway in ATC was identified in 50% of 36 cases (Santarpia et al. 2008).
### Table 4 Proteins expression in anaplastic thyroid carcinoma

<table>
<thead>
<tr>
<th>Protein</th>
<th>Overexpressed</th>
<th>Underexpressed</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cell line</td>
<td>Tumor</td>
<td>Cell line</td>
</tr>
<tr>
<td>Transcription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPARG</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>HNF-1α</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>NKX2-1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOXE1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pax 8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBX7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Id1</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YBX1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HMGI(Y)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOSL1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-myc</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signaling pathway</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>CXCR4</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>pAKT1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pERK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aurora kinases</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>TACC3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kα1 tubulin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topoisomerase-11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proliferation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MKI67</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OEATC-1</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RBBP4</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell cycle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclin D1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclin D3</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Cyclin E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p27</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apoptosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IAPs</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>BCL2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DJ-1</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>NF-κB</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>αB-crystallin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCN2</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Adhesion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cadherin 1, type 1,</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E-cadherin (epithelial)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catenin (cadherin-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>associated protein),</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>beta 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ILK1</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FAK</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

References:
- Hayashi et al. (2004), Aiello et al. (2006) and Copland et al. (2006b)
- Xu et al. (2008)
- Bejarano et al. (2000), Miettinen & Franssila (2000) and Zhang et al. (2006)
- Zhang et al. (2006)
- Pallante et al. (2008)
- Scala et al. (2000)
- Chiappetta et al. (2000)
- Kurihara et al. (2004)
- Ensinger et al. (2004), Schiff et al. (2004), Wiseman et al. (2007b) and Elliott et al. (2008)
- De Falco et al. (2007)
- Santarpia et al. (2008)
- Santarpia et al. (2008)
- Sorrentino et al. (2005) and Ulisse et al. (2006)
- Ulisse et al. (2007)
- Takano et al. (2001)
- Wiseman et al. (2007a)
- Tallini et al. (1999), Ito et al. (2003b), Saltman et al. (2006) and Wiseman et al. (2007a)
- Mizutani et al. (2005)
- Pacifico et al. (2007)
- Wang et al. (2000), Kurihara et al. (2004), Wiseman et al. (2007b) and Lee et al. (2008)
- Baldassarre et al. (1999)
- Wiseman et al. (2007b)
- Saltman et al. (2006)
- Baldassarre et al. (1999) and Tallini et al. (1999)
- Ito et al. (2003a) and Tirro et al. (2006)
- Saltman et al. (2006) and Wiseman et al. (2007a)
- Zhang et al. (2008)
- Starenki et al. (2004) and Meng et al. (2008)
- Mineva et al. (2005)
- Iannetti et al. (2008)
- Dahlman et al. (1998), Husmark et al. (1999), Motyi et al. (2005) and Wiseman et al. (2006, 2007a)
- Wiseman et al. (2007b)
- Younes et al. (2005)
- Kim et al. (2004)
et al. 2008). Both ERK and AKT1 proteins were phosphorylated and, thus, activated in 65–85% of samples, suggesting that these molecules may be important therapeutic targets (Santarpia et al. 2008).

Mitosis

Aurora kinases play an important role in cell division, and dysregulation may result in aneuploidy. Aurora B is overexpressed in ATC cell lines (Sorrentino et al. 2005, Ulisse et al. 2006), and patient samples had a marked increase when compared with normal thyroid tissue or PTCs (Ulisse et al. 2006). Like aurora B, aurora A is overexpressed at both the mRNA and protein levels in ATC cell lines, while Aurora C is increased only at the protein level (Ulisse et al. 2006). Aurora A interacts with RAS and TP53 (Ulisse et al. 2006), both of which are altered in ATC. Aurora A also phosphorylates TACC3 protein. Either over- or under-expression of TACC3 can alter mitosis. Its expression is reduced at the mRNA and protein levels in PTC, FTC, and ATC cell lines, but the lowest level was in anaplastic cells (Ulisse et al. 2007). Microtubules play an important role in mitosis, and overexpression of k±1 tubulin mRNA has been reported in ATC, but not other thyroid malignancies (Takano et al. 2001), and mitotic spindle assembly checkpoint genes mRNAs are also overexpressed (Wada et al. 2008). These observations provide some rationale for the use of microtubule inhibitors in ATC (Ain et al. 2000). Topoisomerase II-α is an enzyme necessary for chromatid segregation, and it was overexpressed in 92% of ATC samples, compared with 42% of differentiated thyroid cancers (Wiseman et al. 2007a).

Proliferation

The MKI67 nuclear antigen has been shown to reflect cellular proliferation rate, with a higher level detected in more aggressive tumors. A high-labeling index, as seen in ATC and poorly differentiated thyroid patients, correlated with persistent disease or death (Tallini et al. 1999). MKI67 positive cells were detected in only 3.9% of 68 PTC patients but in 46.5% of 28 ATCs in one study (Ito et al. 2003b) and in 5% of well-differentiated PTC patients, but in 49% of poorly differentiated and 82% of anaplastic patients in another (Saltman et al. 2006). MIB1, which binds to MKI67, was detected in 100% of ATC samples but only 25% of differentiated thyroid cancers (Wiseman et al. 2007a). OEATC-1 and RbAp48 are two proteins overexpressed in ATC cells and which also influence proliferation (Mizutani et al. 2005, Pacifico et al. 2007).

Cell cycle

Cell cycle regulating genes and proteins (cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors) play a pivotal role in cell proliferation, with up-regulation of CDKs, down-regulation of CDKs, or both being frequent contributors to carcinogenesis. Immunohistochemistry performed on a tissue microarray of 31 ATC samples with 31 molecular markers showed the two most overexpressed proteins were cyclin D1 (100%) and cyclin E (93%) (Wiseman et al. 2007a), confirming a prior report of cyclin D1 overexpression in 77% of 13 ATCs (Wang et al. 2000). Kurihara et al. (2004) found increased cyclin D1 in only 27% of 22 tissues, but Lee et al. (2008) also found cyclin D1 protein in 18 out of the 27 (67%) ATC tumors. Cyclin D3 was also overexpressed in an ATC cell line (Baldassarre et al. 1999). These authors also showed that p27 protein expression was lost in one ATC cell line and reduced in six out of the eight ATC tissues (compared with approximately one-third of PTC and FTC tissues). Normally in the nucleus, p27 was mislocalized to and inactive in the cytoplasm, and correlated with cyclin D3 overexpression (Baldassarre et al. 1999). Tallini et al. (1999) studied well-differentiated, poorly-differentiated, and anaplastic tissues, and found a correlation of low p27KIP1 with larger tumor size, extrathyroidal extension and

<table>
<thead>
<tr>
<th>Protein</th>
<th>Overexpressed</th>
<th>Underexpressed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor suppressor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP53</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Rb</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>p16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTEN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

References

Saltman et al. (2006) and Wiseman et al. (2007a)
Motti et al. (2005)
Lee et al. (2008)
Hou et al. (2008)
survival. Saltman et al. (2006) noted a reduction in several CDKs in more undifferentiated tumors. P21 was detected in 40% of well-differentiated PTCs, only 7% of poorly differentiated thyroid cancers, and 0% of ATCs. For p27, the findings were 13, 8, and 5% respectively. In contrast to others, they observed cyclin D1 positivity in 15, 7, and 0% of cases as tumors became less differentiated.

**Apoptosis**

The inhibitors of apoptosis (IAPs) proteins prevent cells from undergoing apoptosis, and their presence may predict more resistant tumors. One of the IAPs, survivin, was present in 9 out of the 63 (14%) of well-differentiated, 11 out of the 29 (38%) poorly differentiated, and 17 out of the 19 (89%) anaplastic thyroid carcinomas (Ito et al. 2003a). ATC cell lines express several IAPs, including survivin, c-IAP1, c-IAP2, and XIAP (Tirro et al. 2006). By contrast, BCL2 is a proapoptotic protein. Its expression correlated inversely with differentiation (Saltman et al. 2006, Wiseman et al. 2007a). Another protein, DJ-1, protects cells from toxic stresses and higher levels promote insensitivity to TRAIL-induced apoptosis. DJ-1 is expressed in ATC cell lines, and also in more than 88% of follicular and anaplastic thyroid tissues (Zhang et al. 2008). NF-κB, a protein that up-regulates antiapoptotic genes, is also expressed (Starenki et al. 2004, Meng et al. 2008). The small heat shock protein, αβ-crystallin, is regulated by the CRYAB gene and is markedly reduced or absent in ATC tissues and cell line (Mineva et al. 2005). Moreover, the transcription factor, TFCP2L1, involved in CRYAB expression, is down-regulated in ATC (Mineva et al. 2005). By contrast, lipocalin 2 (LCN2), NGAL an NF-κB target, is increased in ATC tissues (Iannetti et al. 2008).

**Adhesion**

Adhesion receptors include cadherins, integrins, selectins, and the immunoglobulin superfamily (Dahlman et al. 1998). Compared with normal thyroid and differentiated cancers, ATCs have reduced cadherin 1, type 1, E-cadherin (epithelial) (Dahlman et al. 1998, Husmark et al. 1999) and increased integrin α2β1 subunit expression (Dahlman et al. 1998). Normal cells at high density become growth arrested at the G1 phase. This process is mediated by the adhesion molecule cadherin 1, type 1, E-cadherin (epithelial), which binds to catenin (cadherin-associated protein), beta 1 or junction plakoglobin and then up-regulates p27KIP. Motti et al. (2005) showed substantial differences in this coordinated response in differentiated (DTC) versus anaplastic cell lines. High cell density promoted catenin (cadherin-associated protein), beta 1 expression in both DTCs and ATCs. By contrast, p27KIP mRNA was increased and protein degradation prolonged in DTC cells during confluence but not in ATC cells (Motti et al. 2005). Thus, reduced cadherin 1, type 1, E-cadherin (epithelial) expression contributes to the increased proliferation, the lack of contact inhibition and propensity to metastasize in ATC cells.

Caderhin 1, type 1, E-cadherin (epithelial) and catenin (cadherin-associated protein), beta 1 expression were examined by IHC in tissue microarrays in 12 cases of ATC that had associated DTC foci. cadherin 1, type 1, E-cadherin (epithelial) was expressed in 92% of the DTC foci, but in only 17% of the ATC tissues. Catenin (cadherin-associated protein), beta 1 was expressed in 67 and 50% respectively (Wiseman et al. 2006). In a 31 marker tissue array, the same authors found that catenin (cadherin-associated protein), beta 1 was one out of the five most strongly overexpressed proteins (Wiseman et al. 2007b). A focal adhesion protein, integrin-linked kinase (ILK), promotes anchorage-independent growth and invasion, and was elevated in ATC cell lines, and the majority of Hurthle cell and anaplastic carcinoma tissues (Younes et al. 2005). By contrast, no ILK expression was detected in ATC tissues (Wiseman et al. 2007b). More studies are necessary to determine its potential role in ATC. Another adhesion protein, focal adhesion kinase (FAK) associates with integrin receptors and is involved with cell migration and survival. FAK is overexpressed in all thyroid tumor types, including ATCs (Kim et al. 2004).

**Tumor suppressors**

The TP53 gene is commonly dysregulated in a variety of cancers. The gene is mutated in anaplastic but not well-differentiated thyroid malignancies, and the protein is also aberrantly overexpressed. TP53 was expressed in 0% of 41 well differentiated, 12% of 43 poorly differentiated, and 32% of 22 ATCs (Saltman et al. 2006). Wiseman et al. (2007b) reported TP53 expression in 61% of ATCs. The same authors examined 12 ATCs with differentiated foci, and detected TP53 in 83% of the anaplastic versus 17% of the differentiated components of the tumors (Wiseman et al. 2007a).

Retinoblastoma protein (pRb) binds to transcription factors and inhibits cell cycle progression when DNA is damaged. It is active in its hypophosphorylated state, and when differentiated thyroid cancer cells became
confluent, pRb became hypophosphorylated, but not in ATC cells (Motti et al. 2005). The tumor suppressor p16 was undetectable in 24 out of the 27 ATC tissues (Lee et al. 2008), and the PTEN gene was hypermethylated in 36 ATC patient samples (Hou et al. 2008).

**Preclinical studies**

**In vitro studies**

**Transcription factors**

PPARG initiates transcription as a heterodimer with RXR isoforms and, in multiple ATC cell lines, inhibits growth via apoptosis (Hayashi et al. 2004), anti-proliferation (Antonelli et al. 2008), p21 reduction of cell cycle progression (Aiello et al. 2006, Copland et al. 2006b), and inhibition of cyclin D1 (Aiello et al. 2006; Table 5). By contrast, the mRNA for retinoic acid receptor, alpha (RARA), involved in transcriptional regulation of 5'-deiodinase, was not induced by retinoic acid in ATC cell lines (Schmutzler et al. 2004). An adenovirus containing an antisense HMGI(Y) gene induced apoptosis and suppressed HMG1(Y) protein synthesis (Scala et al. 2000).

We have shown that a potent PPARG agonist transcriptionally increases PPARG which in turn increases RhoB. RhoB subsequently induces p21WAF1/CIP1 which inhibits cell growth (Copland et al. 2006a,b). In combination with paclitaxel, there is apoptotic synergy.

**Signaling pathways**

The frequent presence of EGFR in ATC tumors, and pleiotropy of its effects, makes it an attractive target for drug development. Gefitinib inhibits cell growth, although high doses are necessary (Nobuhara et al. 2005, Kurebayashi et al. 2006). The monoclonal antibody, cetuximab, also blocks the EGFR and subsequently VEGF gene expression and secretion, but evidence for inducing apoptosis is conflicting (Kurebayashi et al. 2006, Hoffmann et al. 2007). An interesting dual inhibitor of EGFR and VEGFR, AEE788, was shown in ATC cells to increase apoptosis and inhibit both cell proliferation and the phosphorylation of multiple proteins (Kim et al. 2005a, Hoffmann et al. 2007).

Imatinib, another tyrosine kinase inhibitor with multiple targets (e.g., BCR–ABL1; c-KIT; PDGFR), has variable activity in ATC cell lines. Imatinib inhibited phosphorylation of c-ABL1, increased p21, decreased several cyclins, and increased cells in S phase (Podtcheko et al. 2003) and also inhibited growth and induced apoptosis (Kurebayashi et al. 2006). Reduced cell proliferation and the downstream Wnt/catenin (cadherin-associated protein), beta 1 pathway has been observed (Rao et al. 2006). However, the drug may not achieve its effects at clinically achievable concentrations (Dziba & Ain 2004).

Several oncogenes mutated in ATC cells signal through the MAPK-MAPK kinase (MEK)-ERK pathway. In 13 thyroid cell lines, including four ATC lines, two MEK inhibitors inhibited growth, with greater sensitivity in BRAF (+) cells. PD0325901 inhibited pERK, hypophosphorylated Rb, and arrested cells at G1 (Leboeuf et al. 2008). PD0325901 inhibited cell proliferation in RAS or BRAF mutant cells, and synergized with PI3K or NF-κB inhibitors (Liu & Xing 2008).

Stromal cell-derived factor-1 (SDF-1), a ligand for the CXCR4-receptor, stimulated phosphorylation of two downstream kinases, ERK1/2, and AKT1, and subsequently, DNA synthesis in ATC cell lines (De Falco et al. 2007). Several agents, including siRNA CXCR4 and the antagonist, AMD3100, blocked entry of cells into S phase and cell proliferation (De Falco et al. 2007). AKT1 was also phosphorylated by IGF1 in ATC cells, an effect inhibited by thiazolidinediones and possibly PTEN up-regulation (Aiello et al. 2006). AKT1 inhibitor IV also inhibited AKT1 phosphorylation in five ATC cell lines (Hou et al. 2008). Signaling can occur also through c-Jun NH2-terminal kinase (JNK) in ATC cells. The JNK inhibitor, SP600125, with or without ionizing radiation, inhibited cell growth (Bulgin et al. 2006).

**Mitosis**

Aurora kinases are critical in the process of cell division, and Aurora B phosphorylates histone H3. A small molecule Aurora kinase B quinazoline derivative inhibitor reduces phosphorylation and cell proliferation in ATC cell lines (Sorrentino et al. 2005). VX-680 effectively inhibited the cell cycle, reduced colony formation, and increased apoptosis of all Aurora kinases in multiple ATC cell lines (Arlot-Bonnemains et al. 2008).

Paclitaxel, a microtubule stabilizer, inhibited growth in multiple ATC cell lines (Ain et al. 1996, Dziba et al. 2002, Voigt et al. 2005). This agent has multiple effects, including cell cycle arrest, apoptosis, and phosphorylation of multiple signaling kinases (JNK, ERK, AKT1) (Pushkarev et al. 2004). The paclitaxel effects on apoptosis and tubulin acetylation are both enhanced by the histone deacetylase inhibitor, valproic acid (Catalano et al. 2007). Another tubulin-binding agent, combretastatin A4 phosphate, also increased cytotoxicity and, in several ATC cell lines, enhanced the paclitaxel effect (Dziba et al. 2002).
Table 5 Preclinical studies: in vitro

<table>
<thead>
<tr>
<th>Targets</th>
<th>Agonists</th>
<th>Antagonists</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transcription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPARG</td>
<td>TZDs</td>
<td>GW9662; siRNA</td>
<td>Hayashi et al. (2004), Aiello et al. (2006), Copland et al. (2006b) and Antonelli et al. (2008)</td>
</tr>
<tr>
<td>HMG(I(Y)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signaling pathways</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR</td>
<td></td>
<td>Adenoviral-antisense</td>
<td>Scala et al. (2000)</td>
</tr>
<tr>
<td>EGFR/VEGFR</td>
<td>AEE788</td>
<td></td>
<td>Nobuhara et al. (2005) and Kurebayashi et al. (2006)</td>
</tr>
<tr>
<td>EGFR</td>
<td>Cetuximab</td>
<td></td>
<td>Kim et al. (2005a) and Hoffmann et al. (2007)</td>
</tr>
<tr>
<td>BCR–ABL1, c-KIT</td>
<td>Imatinib</td>
<td></td>
<td>Hoffmann et al. (2007)</td>
</tr>
<tr>
<td>MAPKK(MEK)</td>
<td>PD0325901; AZD6244 siRNA; AMD3100 TZD (↓PTEN)</td>
<td>Aiello et al. (2006)</td>
<td></td>
</tr>
<tr>
<td>CXCR4</td>
<td></td>
<td></td>
<td>Hou et al. (2008)</td>
</tr>
<tr>
<td>JNK</td>
<td></td>
<td>PTEN/AKT1</td>
<td>Bulgin et al. (2006)</td>
</tr>
<tr>
<td>Farnesyl transferase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aurora kinases</td>
<td>Aurora kinase inhibitor VX-680</td>
<td>Sorrentino et al. (2005)</td>
<td></td>
</tr>
<tr>
<td>Microtubules</td>
<td>Paclitaxel; combretastatin 4P; valproic acid</td>
<td>Ain et al. (1996), Dziba &amp; Ain (2002), Pushkarev et al. (2004), Voigt et al. (2005) and Catalano et al. (2007)</td>
<td></td>
</tr>
<tr>
<td>Proliferation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OEATC-1</td>
<td>siRNA</td>
<td></td>
<td>Mizutani et al. (2005)</td>
</tr>
<tr>
<td>RBPP4</td>
<td>siRNA</td>
<td></td>
<td>Pacifico et al. (2007)</td>
</tr>
<tr>
<td>Oncolytic viruses</td>
<td>ONX-015; ONX-411; mutant vaccinia; adeno-virus HSV-TK and TP53-regulated Etoposide</td>
<td>Nagayama et al. (2001), Kitazono et al. (2002), Portella et al. (2002), Libertini et al. (2007), Lin et al. (2007, 2008) and Reddi et al. (2008)</td>
<td></td>
</tr>
<tr>
<td>Cell cycle</td>
<td>Gemcitabine</td>
<td></td>
<td>Voigt et al. (2000)</td>
</tr>
<tr>
<td>Cyclins</td>
<td>CCND1 siRNA;</td>
<td></td>
<td>Podtcheko et al. (2003), Bravo et al. (2005) and Lee et al. (2008)</td>
</tr>
<tr>
<td>CDK inhibitors</td>
<td>TPS3 adenovirus</td>
<td></td>
<td>Blagosklonny et al. (1998), Aiello et al. (2006) and Copland et al. (2006b)</td>
</tr>
<tr>
<td>BMP7</td>
<td>siRNA; mithramycin</td>
<td></td>
<td>Franzen &amp; Heldin (2001)</td>
</tr>
<tr>
<td>Apoptosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IAPs</td>
<td>siRNA; Smac</td>
<td></td>
<td>Tirro et al. (2006)</td>
</tr>
<tr>
<td>NF-κB</td>
<td>DHMEQ</td>
<td></td>
<td>Meng et al. (2008)</td>
</tr>
<tr>
<td>IGF1</td>
<td>aIR3 antibody</td>
<td></td>
<td>Poulaki et al. (2002)</td>
</tr>
<tr>
<td>DJ-1</td>
<td>siRNA</td>
<td></td>
<td>Zhang et al. (2008)</td>
</tr>
<tr>
<td>PPARG</td>
<td>TZD</td>
<td></td>
<td>Aiello et al. (2006) and Copland et al. (2006b)</td>
</tr>
<tr>
<td>EGFR/VEGFR</td>
<td>AEE788</td>
<td></td>
<td>Kim et al. (2005a)</td>
</tr>
<tr>
<td>BCR–ABL1; c-KIT</td>
<td>Imatinib</td>
<td></td>
<td>Kurebayashi et al. (2006)</td>
</tr>
<tr>
<td>Aurora kinase</td>
<td>VX-680</td>
<td></td>
<td>Arlot-Bonnemains et al. (2008)</td>
</tr>
<tr>
<td>Integrin-linked kinase</td>
<td>QLT0267</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCN2</td>
<td>siRNA</td>
<td></td>
<td>Younes et al. (2005)</td>
</tr>
<tr>
<td>Polo-like kinase 1</td>
<td>siRNA</td>
<td></td>
<td>Iannetti et al. (2008)</td>
</tr>
<tr>
<td>DUSP26</td>
<td>siRNA</td>
<td></td>
<td>Salvatore et al. (2007)</td>
</tr>
<tr>
<td>Migration</td>
<td></td>
<td></td>
<td>Yu et al. (2007)</td>
</tr>
<tr>
<td>Autotaxin</td>
<td>Autotaxin</td>
<td>IL1B, IL4, TGFβ1</td>
<td>Kehlen et al. (2004)</td>
</tr>
<tr>
<td>VEGFR2</td>
<td>VEGFR2 inhibitor1</td>
<td></td>
<td>Balthasar et al. (2008)</td>
</tr>
</tbody>
</table>
Table 5 continued

<table>
<thead>
<tr>
<th>Targets</th>
<th>Agonists</th>
<th>Antagonists</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein degradation</td>
<td>Bortezomib</td>
<td>Mitsiades et al. (2006) and Conticello et al. (2007)</td>
<td></td>
</tr>
<tr>
<td>Proteasomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epigenetic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histone acetylation</td>
<td>Valproic acid; depsipeptide</td>
<td>Kitazono et al. (2001), Catalano et al. (2006, 2007) and Xing (2007)</td>
<td></td>
</tr>
<tr>
<td>Methylation</td>
<td>5-aza-dCR</td>
<td>Husmark et al. (1999) and Schagdarsurengin et al. (2002, 2006)</td>
<td></td>
</tr>
</tbody>
</table>

Proliferation

OEATC-1, a gene overexpressed in ATCs, is an anonymous gene whose function is unclear. OEATC-1 siRNA had a modest effect of inhibiting cell growth in an ATC cell line, but the mechanism is uncertain (Mizutani et al. 2005). RBBP4 is a gene target of NF-κB, and is overexpressed in ATC tissues and cell lines (Pacifico et al. 2007). Although its function is incompletely understood, an siRNA in FRO cells abolished colony formation in soft agar, and sensitized cell proliferation response to cisplatin and doxorubicin without affecting apoptosis (Pacifico et al. 2007).

Oncolytic viruses can infect cells and lyse them. Beneficial effects in ATC cell lines have been observed with an adenovirus HSV-TK construct and thyroglobulin promoter (Kitazono et al. 2002), with an adenovirus TP53-regulated Cre/loxP system in TP53 mutant cells (Nagayama et al. 2001), and with a mutant vaccinia virus (Lin et al. 2007, 2008), and E1B gene-defective adenovirus (ONYX-015) (Portella et al. 2002). The latter effect was enhanced by lovastatin (Libertini et al. 2007). The oncolytic adenovirus, ONYX-411, reduced cell viability in pRb dysfunctional ATC cell lines (Reddi et al. 2008). Abbosh et al. (2007) developed a conditionally replicative adenovirus therapy that drives Ela and Elb genes in ATC cell lines overpressing the Wnt/catenin (cadherin-associated protein), beta 1 pathway.

Cell cycle

Inhibition of cell cycle progression is an important strategy for reducing tumor growth. The cytotoxic drug gemcitabine in ATC cell lines induced G1/S arrest, and the effect was additive if followed by CDDP. Of interest, these drugs given in reverse order produced an antagonistic response as CDDP inhibits gemcitabine incorporation into DNA (Voigt et al. 2000). Imatinib increased cells in S phase. The CDK inhibitors, p21^{cip1/waf1}, and p27^{kip1}, were increased, and cyclins A and B1, and CDC2, were inhibited (Podtcheko et al. 2003). Bone morphogenetic protein 7 (BMP7), a member of the TGFB1 superfamily, caused growth inhibition in four ATC cell lines by up-regulating p21^{cip1} and p27^{kip1}, and by inhibiting CDK2 and CDK6 activity and Rb phosphorylation (Franzen & Heldin 2001). Other agents shown to have cytostatic effects on the cell cycle include the marine derived plitidepsin (Bravo et al. 2005), TP53-expressing adenovirus (Blagosklonny et al. 1998), and thiazolidinediones (TZDs) (Podtcheko et al. 2003, Aiello et al. 2006, Copland et al. 2006b, Bonofiglio et al. 2008). TZDs exert their growth inhibitory effect via PPARG transcriptional activation, and subsequent p21 activation (Aiello et al. 2006, Copland et al. 2006b) and involves Sp1 interaction, as it is inhibited by siRNAs to p21 or Sp1, and also by the Sp1 inhibitor, mithramycin (Bonofiglio et al. 2008). We have also shown that the PPARG activation of p21 is Rho B dependent and inhibited by Rho B siRNA (Copland et al. 2006a).

Cyclin D1 is overexpressed in HTh7 cells, and an siRNA for CCND1 inhibits both cyclin D1 mRNA and protein, but has minimal effect on cell growth (Lee et al. 2008).

Apoptosis

An important regulator of the life of cells is apoptosis, a process influenced by numerous pro- and antiapoptotic proteins and pathways. The IAPs, survivin, and C-IAP1, are increased, while the endogenous inhibitor, Smac, is reduced after chemotherapy; this response, thus, produces chemoresistance, a phenomenon seen in multiple tumors (Tirro et al. 2006). Several potential targets include the IAPs, as siRNA to c-IAP1, and survivin (Tirro et al. 2006) or inhibition of the IAPs by NF-κB inhibition (Meng et al. 2008) both restore sensitivity to cytotoxic drugs. Overexpression of Smac is effective in enhancing cell death in resistant cells (Tirro et al. 2006), and inhibition of nuclear translocation of NF-κB also potentiates taxane-induced apoptosis (Meng et al. 2008).
The growth factor, IGF1, protects FRO cells from TRAIL-induced apoptosis, an effect that can be abrogated by the IGF1 receptor antibody, aIR3 (Poulaki et al. 2002). Another anti-apoptotic protein, DJ-1, also renders cells less sensitive to TRAIL-induced apoptosis. Inhibition of DJ-1 by siRNA, or overexpression of DJ-1, can sensitize or make cells less sensitive to TRAIL-induced apoptosis (Zhang et al. 2008). AEE788, the dual inhibitor of EGFR and VEGFR, induced ~35% suppression in two ATC cell lines at the IC50 drug concentration (Kim et al. 2005a). Other apoptotic drugs in ATC cell lines include imatinib (Kurebayashi et al. 2006), VX-680 (Arlot-Bonnemains et al. 2008), and an integrin-linked kinase inhibitor, QLT0267 (Younes et al. 2005). Lipocalin 2 (LCN2) enhances survival by increasing iron-dependent nucleotide metabolism and reducing apoptosis (Iannetti et al. 2008).

The serine/threonine kinase, polo-like kinase 1 (PLK1), can be decreased when either TP53 or p21 are overexpressed, and apoptosis is increased by siRNA PLK1 (Salvatore et al. 2007). The DUSP26 gene (coding for a MAPK phosphatase) is overexpressed in ATC cell lines, as is the protein in tumors (Yu et al. 2007). DUSP26 dephosphorylates p38, a regulator of apoptosis upstream of caspase-3. A DUSP26 siRNA was effective in activating caspase-3 and increasing apoptosis (Yu et al. 2007).

**Migration**

Little is known about motility in ATC cells. Autotaxin (ATX) is a motility promoting protein in a number of tumors. Higher levels of ATX mRNA were expressed in anaplastic versus other thyroid malignancies, and was increased in ATC cell lines also (Kehlen et al. 2004). In the 1736 cell line, IL1B, IL4, and TGFB1 suppressed, while EGF and bFGF stimulated ATX mRNA. Functionally, when ATX was transfected into UTC-1736 cells, migration was enhanced (Kehlen et al. 2004). Balthasar et al. (2008) showed that the VEGFR2 inhibitor 1 attenuated cell migration in FRO cells. Although they showed that sphingosine-1-phosphate stimulated VEGFA secretion, suggesting crosstalk between the G-protein coupled S1P receptor regulating migration and the VEGFR tyrosine kinase receptor, a high concentration of S1P was required (Balthasar et al. 2008). Thus, the mechanism of VEGFR affecting migration in FRO ATC cells is unclear.

**Protein degradation**

Proteins are degraded in the 26S proteasome, some of which play important roles in reducing cell growth. Bortezomib is a proteasome inhibitor that prevented degradation of TP53, p21, and the inhibitor of NF-κB (i.e., IκB) cleaved caspases leading to apoptosis and synergized with doxorubicin in ATC cell lines (Mitsiades et al. 2006). Conticello et al. (2007) confirmed the p21 and apoptosis effects of bortezomib and showed that TRAIL-mediated cytotoxicity was increased.

**Epigenetics**

Epigenetic silencing of genes occurs through deacetylation or methylation. Kitazono et al. (2001) showed that depsipeptide increased histone H3 acetylation and growth inhibition in SW-1736 cells. Several thyroid specific mRNAs, sodium iodide symporter and thyroglobulin, as well as 125I uptake, were enhanced. Valproic acid (VPA), another histone deacetylase inhibitor, increased the acetylation of H4 histone, resulting in enhanced doxorubicin-mediated apoptosis and G2 cell cycle arrest (Catalano et al. 2006). The same authors showed that valproic acid, while having no independent effect on apoptosis, also enhanced the paclitaxel effect (Catalano et al. 2007); they also showed that VPA induced tubulin acetylation. Xing (2007) reviewed several studies showing that thyroid specific genes (e.g., Na+I- symporter, thyroid peroxidase, and thyroglobulin) as well as iodide uptake could be restored by deacetylase inhibition in poorly differentiated and ATCs.

Husmark et al. (1999) showed that 5-aza-2'-deoxycytidine (5-Aza), a demethylating agent, could up-regulate cadherin 1, type 1, E-cadherin (epithelial) and junction plakoglobin in ATC cell lines. Two genes frequently epigenetically silenced through CpG island promoter methylation are the RAS association domain family 1A gene (RASSF1A) and the CDK inhibitor, p16INK4a. RASSF1A, located on chromosome 3p21, may also lose function from loss of heterozygosity. Schagdarsurengin et al. (2002) reported high levels of methylation of both genes in ATC tissues, and of RASSF1A in cell lines, and that treatment with the methylation inhibitor, 5-aza-2’-deoxycytidine, restored transcriptional activity. The same authors subsequently analyzed the methylation status of 17 gene promoters in nine ATC tissues and five ATC cell lines. Compared with other thyroid cancers, ATCs had a significant increase in methylation of five genes: p16INK4a (cell cycle), death associated protein kinase (DAPK) and UCHL1 (apoptosis), MGMT (DNA repair), and TSHR (Schagdarsurengin et al. 2006). 5-Aza successfully restored gene expression in all four ATC cell lines tested.
In vivo studies

Studies in vivo provide further confirmation of a drug or other agent’s effect, and are extremely important to perform prior to considering human clinical trials. The nude mouse xenograft model has been used almost exclusively for the small number of reports published in preclinical studies of ATC (Table 6). Imatinib and gefitinib both inhibit tumor growth (Podtcheko et al. 2003, Nobuhara et al. 2005, Kurebayashi et al. 2006). Kim et al. (2005a) showed that dual inhibition of EGFR and VEGFR, in combination with paclitaxel, is effective. Mechanistically, AEE788 reduced tumor cell autophosphorylation of EGFR and MAPK, and endothelial cell EGFR and VEGFR2 phosphorylation both singly and with paclitaxel. Microvessel density was decreased and apoptosis increased (Kim et al. 2005a). The MEK inhibitor, AZD6244, blunted tumor growth, and pERK (Leboeuf et al. 2008). The tubulin-binding agent, combretastatin A4P, was equally effective in growth inhibition (Dziba et al. 2002), while CXCR4 inhibition with AMD3100 inhibited tumor growth by more than 90% (De Falco et al. 2007).

The farnesyl transferase inhibitor, manumycin, was completely effective in inhibiting growth and, in combination with paclitaxel, inhibited angiogenesis in the animal model (Xu et al. 2001). An oncolytic vaccinia virus (GLV-1h68) produced almost complete inhibition of xenograft growth when injected intratumorally (Lin et al. 2008), while the oncolytic virus, ONXY-015, produced a modest inhibition of tumor growth. The effect was more than doubled by lovastatin due, at least in part, to increased viral replication (Libertini et al. 2007). An LCN2 siRNA markedly inhibited growth of FRO cell tumors in nude mice, suggesting a possible NF-κB pathway target for therapeutics (Iannetti et al. 2008). DHMEQ, an inhibitor of NF-κB translocation, also inhibited tumor growth as a single agent, and synergized with docetaxel (Meng et al. 2008).

Future in vivo studies would benefit from an orthotopic model, which recreates the clinical presentation of local neck invasion and distant metastases (Kim et al. 2005a,b).

Clinical management

The rarity of anaplastic thyroid carcinoma limits the number of patients seen annually, even at referral centers. Thus, most series have accrued patients over several decades (Table 7). Comparisons across reported studies are confounded by the variety of treatments tried over these extended periods of time, and by the paucity of controlled clinical trials.

McIver et al. (2001) reviewed the 50-year experience with 134 patients at the Mayo Clinic. The primary tumor size averaged 7 cm (range: 2–16 cm), and 46% had distant metastases on presentation. Ninety-six (72%) of patients received some surgery (attempt at cure in 35 or debulking in the rest) and most received

<table>
<thead>
<tr>
<th>References</th>
<th>Cell line</th>
<th>Agent</th>
<th>Growth inhibition (%)</th>
<th>Treatment (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurebayashi et al. (2006)</td>
<td>KTC-3</td>
<td>Imatinib</td>
<td>44%</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gefitinib</td>
<td>53%</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Both</td>
<td>62%</td>
<td>14</td>
</tr>
<tr>
<td>Podtcheko et al. (2003)</td>
<td>FRO</td>
<td>Imatinib</td>
<td>~67%</td>
<td>14</td>
</tr>
<tr>
<td>Nobuhara et al. (2005)</td>
<td>ACT-1</td>
<td>Gefitinib</td>
<td>&gt;90%</td>
<td>28</td>
</tr>
<tr>
<td>Kim et al. (2005a)</td>
<td>K4</td>
<td>AEE788</td>
<td>58%</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paclitaxel</td>
<td>44%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Both</td>
<td>69%</td>
<td></td>
</tr>
<tr>
<td>Leboeuf et al. (2008)</td>
<td>Cal62</td>
<td>AZD6244</td>
<td>~75%</td>
<td>27</td>
</tr>
<tr>
<td>Dziba et al. (2002)</td>
<td>BHT101</td>
<td>Combretastatin A4P</td>
<td>~60%</td>
<td>20</td>
</tr>
<tr>
<td>De Falco et al. (2007)</td>
<td>BHT101</td>
<td>AMD3100</td>
<td>92%</td>
<td>21</td>
</tr>
<tr>
<td>Xu et al. (2001)</td>
<td>Hth74</td>
<td>Manumycin</td>
<td>~100%</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paclitaxel</td>
<td>~100%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Both</td>
<td>~100%</td>
<td></td>
</tr>
<tr>
<td>Lin et al. (2008)</td>
<td>8505C</td>
<td>Mutant vaccinia</td>
<td>~96%</td>
<td>90</td>
</tr>
<tr>
<td>Libertini et al. (2007)</td>
<td>FRO</td>
<td>Lovastatin</td>
<td>–</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dl1520 (ONYX-015)</td>
<td>23%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Both</td>
<td>~55%</td>
<td></td>
</tr>
<tr>
<td>Iannetti et al. (2008)</td>
<td>FRO</td>
<td>LCN2 siRNA</td>
<td>~97%</td>
<td></td>
</tr>
<tr>
<td>Meng et al. (2008)</td>
<td>FRO</td>
<td>DHMEQ</td>
<td>&gt;90%</td>
<td>14</td>
</tr>
</tbody>
</table>
external beam radiotherapy (XRT) post-operatively. Surgery and XRT had a modest effect on survival compared with palliation alone (3.5 and 2.3 months, versus 3 weeks). Interestingly, the longest survivor (23 years) had surgery alone for a 6.1 cm primary tumor with 3 lymph nodes involved. Multimodal therapy (surgery, XRT, and radiosensitizing chemotherapy) was used in 13 patients; median survival was unaffected, although there was a trend toward an improved 1 year survival.

**Junor et al. (1992)** treated 91 patients in Glasgow, UK, from 1961 to 1986. Those who had surgery (5-total thyroidectomy; 28-partial thyroidectomy) had improved survival. Eighty-six patients received radiotherapy, and the dose did not alter survival; neither did chemotherapy improve survival.

**Levendag et al. (1993)** treated 51 patients from 1970 to 1986. Twenty-three had surgery (‘total’ resection in 15, with negative margins in one, and incisional biopsy in eight). Median survival was 3.4 months in the thyroidectomy group, and 2.7 months in the biopsy only patients. All received radiotherapy, but > 30 Gy in only 57%. Overall, survival at 1 year was 6%. Higher doses of radiation provided some advantage, with a 1 year survival of 10% in those receiving ≥ 30 Gy, and 20% if the extrapolated tolerance dose > 60 Gy.

In Helsinki, Finland, 33 patients had surgery over 27 years, although total thyroidectomy could be done in but 11 patients (Voutilainen et al. 1999). At diagnosis, 48% had distant metastases. Radiotherapy and cytotoxic drugs were individualized, and neither the radiation schedule nor chemotherapeutics used were provided. Predictors of survival included: tumor resectability, radiotherapy, and distant metastases at diagnosis.

At the Roswell Cancer Institute, 21 patients were treated between 1968 and 1992 (Tan et al. 1995). Five had complete resection, 18 received XRT, and six were given adriamycin +/− one or more other agents. Overall, the median survival was 4.5 months and 2-year survival was 14%. Of the five who had complete resection, the 5-year survival was 60% (only three had XRT + chemo; one had XRT only, and one had only surgery). Twelve patients had incomplete resections; none lived for 2 years.

**Pierie et al. (2002)** treated 67 patients from 1969 to 1999. Complete resection was achieved in 12 (eight of whom had incidental ATC discovered at surgery). Survival was highest after complete resection and least with no resection (1 year: 93 and 4% respectively). Radiation doses > 45 Gy improved survival compared with lower doses, and chemotherapy had no significant effect (Pierie et al. 2002).

**Kim & Leeper (1983)** introduced the strategy of low-dose adriamycin (10 mg/m² per week) with hyperfractionated radiotherapy (160 rads twice a day, 3 days a week: total dose = 5760 rads). Two patients died within 2 weeks; nine others had completed treatment, and seven had complete local responses. Median survival of the nine treated patients was
~ 10 months. Only one patient had complete thyroid resection, while five had partial resection and three biopsy only distant metastases at diagnosis.

In Japan, 16 patients were treated with conventional XRT from 1971 to 1983, and chemotherapy included adriamycin, mitomycin C, or cyclophosphamide. An additional 21 received hyperfractionated XRT with adriamycin and/or cisplatin from 1984 to 1993. Twenty-four had surgery. Of the 19 with complete resections, the 1 year survival was 20%, while no one with residual disease after surgery survived a year (Kobayashi et al. 1996).

One of few prospective clinical trials was conducted by the Eastern Cooperative Oncology Group (Shimaoka et al. 1985). From 1976 to 1982, 21 patients were randomized to doxorubicin versus 18 to doxorubicin plus cisplatin. The single agent group had no complete and one partial response while the two-drug regimen produced three complete, and three partial remissions (5% vs 33%; p = 0.03). Median survival was 2.7 months, but two CRs were long-lasting at 41.3 and 34.7 months, with one patient treated with thyroidectomy and radiotherapy, and the other only a biopsy.

Schlumberger et al. (1991) reported their 10-year experience with a combination of chemotherapy and external beam radiotherapy. Patients ≤ 65 years (n = 12) received doxorubicin and cisplatin every 4 weeks with XRT during the first four cycles. Two were disease-free after surgery, and one was alive at 34 months. Four had small neck disease at time of the therapy, and had CRs of 4, 6, 8, and 22 months. Six had initial distant metastases and were dead within 6 months. Eight patients ≥ 61 years received mitoxantrone every 4 weeks, with radiotherapy. Two had no detectable disease post-operatively and one had a 40-month remission. Three had initial neck disease only, but no surgery and three had distant metastases. The longest response was 8 months.

The Japanese Society of Thyroid Surgery performed a pilot study of intensive chemotherapy in 17 patients from 1992 to 1994 (Chemotherapy Committee The Japanese Society of Thyroid Surgery 1995). Therapy included cisplatin, adriamycin, etoposide, peplomycin, and granulocyte colony-stimulating factor every 3 weeks with local XRT after one cycle. Ten patients had advanced disease, only four received XRT, and two had PRs of 2 and 3 months. Seven patients had no residual disease after thyroidectomy, six received adjuvant chemotherapy, and five received XRT. Three were alive without recurrence at 3, 11, and 11 months.

Mitchell et al. (1999) treated 17 patients with aggressive radiation (twice daily, 5 days a week, 20–24 days, total dose = 60.8 Gy) to see whether they could improve local control. Only one patient had prior thyroidectomy, six had debulking, seven had a biopsy, and three had fine needle aspiration. Clinical responses (partial or complete) were achieved in 59%, and stable disease in 29%, with local control maintained in 76%. However, all patients died within 8 months, and the authors concluded that toxicity was unacceptable.

Eighty-one patients from the Stockholm–Götland region of Sweden were treated during a 27-year period (Nilsson et al. 1998). There were six separate time frames during which the type of chemotherapy and radiotherapy given were varied. As surgery was performed more frequently and radiation therapy was accelerated and hyperfractionated, local disease recurrence was substantially reduced. Unfortunately, overall survival was not improved and, in fact, was shortened. Results in these Swedish patients during the era of doxorubicin were summarized (Tennvall et al. 2002). Of 55 patients treated over 15 years, 40 had surgery initially. While local control occurred in 60%, median, and 1 year survival were similar to other reports.

Haigh et al. (2001) managed 33 patients and found that surgical resection with curative intent in eight resulted in a median survival of 43 months and 5-year survival of 50%. Most also received XRT, and a broad spectrum of chemotherapeutic agents was used. In 18 patients with palliative surgery and seven who received chemotherapy and XRT without surgery, the median survivals were 3 and 3.3 months. Thus, patients whose tumor could be visibly resected had a much better chance of treatment response.

In Slovenia, Besic et al. (2005) treated 188 patients between 1972 and 2003. Factors favoring survival were age (< 70 years), good performance status, slow tumor growth, and lack of extrathyroidal extension or distant metastases. In an earlier report of 162 patients (Besic et al. 2001), survival was similar in those who had primary surgery versus primary radiotherapy and/or chemotherapy. However, median survival was best in patients who had primary chemo- and radiotherapy and in whom surgery could then be performed (Besic et al. 2001).

De Crevoisier et al. (2004) treated 30 patients over 10 years in a prospective protocol combining surgery, chemotherapy, and radiotherapy. Their patients differed in that only 6 out of the 30 had distant metastases at presentation. Surgery was followed by chemotherapy (doxorubicin plus cisplatin) every 4 weeks starting 3 weeks after surgery, and hyperfractionated accelerated XRT after cycle two. Nine patients had visibly complete resection, and seven had complete remission (none had initial tracheal extension). Of the nine with complete resection, six had mixed ATC, and three had
<20% ATC. The median survival of all patients was 10 months, while one and 3-year survivals were 46 and 27% respectively.

Wang et al. (2006) treated 47 patients with radiotherapy from 1983 to 2004. Twenty-three patients with good performance status and no distant metastases received radical radiotherapy (>40 Gy), while 24 with poor performance status or distant metastases received palliative therapy (<40 Gy). Overall, median survival was 5.6 months (11.1 and 3.2 months respectively).

In Turin, Italy, 27 patients were treated in a 5-year period (Brignardello et al. 2007). Surgery was performed initially (maximum debulking in 11 and palliative in six). Chemotherapy (doxorubicin + cisplatin) was given during and after radiation. The approach in five patients was neo-adjuvant chemo/XRT followed when possible by surgery, while five others had paclitaxel therapy alone. As in other series, surgical resection was the major contributor to patient responses. While median survival was only 3.9 months, those with maximal debulking had a 6-month survival of 58%; those with palliative or no surgery, only 10%.

Twelve population-based cancer registries in the NCI’s Surveillance, Epidemiology, and End Results (SEER) database from 1971 to 2000 were reviewed (Kebebew et al. 2005). There were 516 patients (171 men, 345 women) with a mean age of 71.3 years at diagnosis of ATC. The 1 year survival was 19.3%, and favorable predictors were age <60 years, intrathyroidal disease, and combined use of surgery and radiotherapy.

Based on preclinical data (Ain et al. 1996), an open–label phase 2 clinical trial of paclitaxel as a 96-hour infusion was conducted (Ain et al. 2000). Prior surgery included thyroidectomy, lobectomy, or biopsy in 8, 3, and 8 patients respectively. Disease progression occurred in 42%, while stable disease (5%), partial regression (47%) or complete regression (5%) was observed in the remainder. Overall, survival was 6 months, with a median survival of 32 weeks in the ten responders, and only 7 weeks in eight non-responders.

New therapies

Thyroid trials

Three studies of novel targeted agents have included a limited number of ATC patients. Three ATC patients in a phase 1 study received combretastatin A-4 phosphate, one of whom had a complete remission and was alive at 30 months (Dowlati et al. 2002). In a phase 1 trial of intermittent high-dose gefitinib and docetaxel, one patient had ATC, and experienced a 4-month partial remission (Fury et al. 2007). Two ATC patients enrolled in a phase 2 trial with axitinib; one had a partial remission (duration unknown), and one progressive disease (Cohen et al. 2008).

A review of www.clinicaltrials.gov on June 30, 2008 showed the following trials listed for ATC. Phase 2 thyroid specific trials included four completed (two with combretastatin, one with intensified combination hydroxyurea/paclitaxel and hyperfractionated XRT, and one with irofulven/capecitabine); two were active/not recruiting (imatinib, gefitinib); and four recruiting (sorafenib, pazopanib, sunitinib, and combination PPARG agonist, CS-7017/paclitaxel).

There were five phase 1 trials listed that included ATC patients as eligible. Two trials were completed (SU5416/paclitaxel and tipifarnib/trastuzumab), two were active/not recruiting (IL-12/trastuzumab, NGR–TNF (European study)), and one was recruiting (sorafenib/bevacizumab).

Results from these studies will hopefully provide insight into which newer agents might be tested further.

Potential agents

It should be mentioned that several ATC cell lines, including DRO, ARO, and KAT4, may be derived from cancers other than anaplastic thyroid tumors (Schweppe et al. 2008). Given this concern, we have not cited results that used only these cell lines. However, it would be worthwhile repeating these studies with other confirmed ATC cell lines, as there are some interesting additional potential therapeutic targets.

There are many potential therapeutic targets for this deadly disease, as listed in Tables 1, 3–7. A number of articles have reviewed the many pathways that have applicability to ATC, and have discussed a variety of agents being developed. The reader is referred to the following recent reviews for details: chromosomal abnormalities (Frohling & Dohner 2008), oncogenes (Croce 2008), RET, and RAS–MAPK pathways (Santoro & Carlomagno 2006, Sebolt-Leopold 2008, Williams & Smallridge 2004), AKT1 (Shinohara et al. 2007), c-MET (Salgia 2008), angiogenesis (Kerbel 2008), EGFR (Ciardiello & Tortora 2008), apoptosis (Ferreira et al. 2002, Altieri 2008, Vucic 2008), mitosis (Strebhardt & Ullrich 2006, Bhat & Setaluri 2007, Gaitschi et al. 2008), Hsp 90 (Bishop et al. 2007), epigenetics (Xing 2007, Esteller 2008), farnesyl transferases (Appels et al. 2005), proteasomes (Orlowski & Kuhn 2008), tumor microenvironment...
(Blansfield et al. 2008, Parsons et al. 2008), and microRNAs (Jeyaseelan et al. 2007).

**Future directions**

Survival of patients with ATC has changed little in the past 50 years, despite more aggressive systemic and radiotherapies. Much has been learned about the genes, RNAs, and proteins dysregulated. Given the genomic instability of ATC, effective therapies may benefit from comprehensive microarray analysis (Shai 2006) or genome-wide screening (Sultan et al. 2008) to develop an individualized therapeutic regimen that maximally inhibits major pathways at multiple genetic and epigenetic levels. In addition, to more fully characterize the complex molecular profile, subsequent rapid *in vitro* screening assays of combinations of targeted therapies may further optimize a patient’s treatment plan. Finally, refinement may derive from evolving drug delivery systems such as nanoparticles (Cho et al. 2008).

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This work was funded in part from NIH grant P30CA15083 (Cancer Center Support Grant, RCS), Mayo Clinic Research Committee (RCS), Florida Department of Health Bankhead Coley grant (JAC, RCS) and a grant for rare cancers from Dr Ellis and Dona Brunton (JAC). Drs Smallridge and Copland are investigators in a clinical trial of anaplastic thyroid carcinoma funded by Daiichi Sankyo Pharma Development.

**Acknowledgements**

The authors thank Dr Stefan Grebe for reviewing the manuscript.

**References**


Copland JA, Marlow LA, Gumz M, Kreinest PA, Kurakata S, Fujiwara K, McIver B, Sebo T & Smallridge RC 2006a Peroxisome proliferator activated receptor gamma (PPARγ) transcriptionally regulates RhoB, a tumor suppressor essential for PPARγ mediated antitumor


Dziba JM, Marcinek R, Venkataraman G, Robinson JA & Ain KB 2002 Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 12:1063–1070.


Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL & Tallini G 2001 Beta-catenin dysregulation in...


Kebebew E, Peng M, Treseler PA, Clark OH, Duh QY, Ginzinger D & Miner R 2004 Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue


Namification 2004 Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocrine Pathology 15 319–327.


Quirós RM, Ding HG, Gattuso P, Prinz RA & Xu X 2005 Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. *Cancer* **103** 2261–2268.


Takahara S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogouenovitch TI, Nakazawa Y, Hayashi T, Ohtsuru A...


---

*www.endocrinology-journals.org*


